Patient Resources for

CDKL5 Deficiency Disorder (CDD)

CDKL5 Deficiency Disorder (CDD) is a serious and rare genetic disorder that is caused by a mutation of the cyclin-dependent kinase-like 5 (CDKL5) gene, located on the X chromosome.

The CDKL5 gene encodes proteins essential for normal brain function. Mutations in the gene are usually spontaneous ‘de novo’ occurrences, rather than inherited. Initially, CDKL5 mutations had been found in children diagnosed with cerebral palsy and autism, among other conditions, and the resulting disorder was classified as an early-onset seizure variant of Rett Syndrome. It is now known to be an independent clinical entity caused by mutations in a distinct X-linked gene and therefore a separate disorder with its own distinct characteristics.

Learn About the Marigold Clinical Trial

How does CDD affect the body?

CDD predominantly affects girls and is characterized by early-onset, difficult-to-control seizures and severe neuro-developmental impairment. Most children affected by CDD cannot walk, talk, or feed themselves, and many are confined to wheelchairs, dependent on others for everything. Many also suffer from scoliosis, visual impairment, sensory problems, gastrointestinal difficulties, and sleeping disorders. Currently, there are no approved therapies for CDD.

Where can I find more information on CDD?

You can find additional educational and support resources on CDKL5 Deficiency Disorder through the following foundations and patient advocacy groups:

Links to third party sites are provided for convenience purposes only. The information contained on these sites is not information provided, controlled or monitored by Marinus Pharmaceuticals in any way. Marinus Pharmaceuticals is not responsible in any way for the accuracy, completeness or fitness for any particular purpose of any content appearing on such sites.

“A Journey of Emotions as a CDKL5 Family”

A mom of a child with CDD expresses the journey of emotions endured by these families.

compassionate use policy

G’s Story

“Meet our special little guy G, who enjoys creating beautiful pieces of art with his mommy to help raise awareness for CDKL5.

Follow us on Facebook at Art for Hope/Love/Cure and on Instagram @artforhopelovecure.”

Read More About G and Other Stories

marigold field bg



Clinical Development of Ganaxolone in CDKL5 Deficiency Disorder

Top-line data from a Phase 2 open-label study in seven patients with CDKL5 deficiency disorder (CDD) showed that oral ganaxolone, in addition to baseline treatment, provided a sizable and durable seizure-frequency reduction in the majority of patients, with some achieving an increase in the number of seizure-free days and reporting behavioral benefits.  Four patients continued in the one year extension to the study and continue to show a sizable and durable reduction in their seizure frequency.


icon-liquid.pngLiquid Suspension & Oral Dosing

Ganaxolone was generally safe and well-tolerated with no serious adverse events. Based upon these robust CDD clinical results and etiologic fit with ganaxolone’s mechanism of action, we have prioritized CDD as our lead pediatric orphan program for advancement into later stage clinical development.


The Marigold Study is a global pivotal clinical study in children with CDKL5 deficiency disorder. Marinus has completed this Phase 3 trial.

To learn more about the study, visit

logo marigold study

icon science pipeline

About the Science

See how ganaxolone works as a new mechanism of action.


icon bibilography


Find publications referencing ganaxolone and its affect on seizures and neuropsychiatric disorders.